語系:
繁體中文
English
說明(常見問題)
回圖書館首頁
手機版館藏查詢
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
FindBook
Google Book
Amazon
博客來
Dual Functional Liposomes for Improved Cancer Cell Targeting and Enhanced Intracellular Delivery.
紀錄類型:
書目-電子資源 : Monograph/item
正題名/作者:
Dual Functional Liposomes for Improved Cancer Cell Targeting and Enhanced Intracellular Delivery./
作者:
Deshpande, Pranali Prabhakar.
面頁冊數:
1 online resource (150 pages)
附註:
Source: Dissertations Abstracts International, Volume: 79-10, Section: B.
Contained By:
Dissertations Abstracts International79-10B.
標題:
Pharmaceutical sciences. -
電子資源:
http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10259198click for full text (PQDT)
ISBN:
9780355772838
Dual Functional Liposomes for Improved Cancer Cell Targeting and Enhanced Intracellular Delivery.
Deshpande, Pranali Prabhakar.
Dual Functional Liposomes for Improved Cancer Cell Targeting and Enhanced Intracellular Delivery.
- 1 online resource (150 pages)
Source: Dissertations Abstracts International, Volume: 79-10, Section: B.
Thesis (Ph.D.)--Northeastern University, 2017.
Includes bibliographical references
Cancer therapy has undergone remarkable changes in recent times making great progress. However, there still remains an unmet need to completely cure cancer. A major limitation of cancer therapy is the undesired effects on non-target tissues. Using targeted nanocarriers like liposomes can help to enhance delivery of therapeutics to a pathological area, influence the pharmacokinetic profile of the drug and enhance its accumulation in the targeted sites. Modification of the liposome surface is critical for control of liposomal properties and therefore, their biological behavior. Polyethylene glycol (PEG)-modified liposomes have enhanced longevity in blood by escaping clearance by the reticulo-endothelial system (RES), resulting in increased accumulation at the tumor sites via passive targeting owing to the enhanced permeability and retention (EPR) effect. In this study, we took advantage of passive, active and intra-cellular targeting capabilities of liposomes for cancer therapy by modifying their surface with ligands. PEG coated DOX-loaded liposomes were surface-modified with an intracellular delivery agent, octa-arginine (R8) peptide, to facilitate improved cytosolic delivery of DOX. R8 was attached to the distal end of the PEG chain, in a polyethylene glycol-phosphatidylethanolamine (PEG-PE)-based amphiphilic polymer for conjugation with the liposome bilayer and improved access to its site of cellular interaction. Once the R8-coated DOX-loaded liposomes entered the tumor tissue by passive targeting, the exposed R8 was expected to bring about intracellular penetration of the liposomes and cytosolic delivery of DOX. Cellular uptake of these liposomes studied by confocal microscopy and flow cytometry in cancer cells in vitro, highlighted advantages of R8 as a tool for intracellular delivery of the payload, compared to the unmodified liposomes. R8-modified liposomes illustrated superior effects in terms of in vitro cytotoxicity and apoptosis and good tumor growth inhibition in vivo. However, the interaction of R8-liposomes with cancer cells is non-specific. To make the formulation cancer cell-targeted, a second ligand was added to the liposome surface. Dual functional liposomes (DualL) were prepared by modification of liposome-surface with transferrin molecules, in combination with the R8-modification, to target the transferrin receptors (TfRs) that are known to be over-expressed on the surface of many cancer cells. Fluorescently labelled DualL, without the DOX payload, were tested for their interactions with TfR over-expressing A2780 ovarian cancer cells. Flow cytometry and confocal microscopy, clearly indicated better association and internalization of DualL versus R8L, pointing to the involvement of both ligands in these effects. When loaded with DOX, Dual DOX-L showed augmented selective cytotoxicity towards cancer cells versus non-cancer cells in vitro. Cytotoxicity of R8 DOX-L was equivalent in the tested cancer and non-cancer cell lines presenting proof of their non-specificity towards cancer cells. The therapeutic potential of Dual DOX-L was tested in vivo in an A2780 ovarian xenograft model in nude mice. In tumor-bearing mice, higher distribution and accumulation of DOX in tumors was obtained upon i.v. administration of Dual DOX-L compared to other treatment groups. A tumor growth inhibition study demonstrated a clear pattern of suppression in tumor growth for Dual DOX-L treated tumors along the course of treatment. On the whole, these results favor the idea of modification of liposome-surfaces with combinations of ligands that have properties of both cancer-cell targeting and improved intracellular delivery to enhance efficacy of their payloads for cancer therapy.
Electronic reproduction.
Ann Arbor, Mich. :
ProQuest,
2023
Mode of access: World Wide Web
ISBN: 9780355772838Subjects--Topical Terms:
3173021
Pharmaceutical sciences.
Subjects--Index Terms:
CancerIndex Terms--Genre/Form:
542853
Electronic books.
Dual Functional Liposomes for Improved Cancer Cell Targeting and Enhanced Intracellular Delivery.
LDR
:05218nmm a2200421K 4500
001
2358453
005
20230815054812.5
006
m o d
007
cr mn ---uuuuu
008
241011s2017 xx obm 000 0 eng d
020
$a
9780355772838
035
$a
(MiAaPQ)AAI10259198
035
$a
(MiAaPQ)northeasternbouve:10317
035
$a
AAI10259198
040
$a
MiAaPQ
$b
eng
$c
MiAaPQ
$d
NTU
100
1
$a
Deshpande, Pranali Prabhakar.
$3
3698982
245
1 0
$a
Dual Functional Liposomes for Improved Cancer Cell Targeting and Enhanced Intracellular Delivery.
264
0
$c
2017
300
$a
1 online resource (150 pages)
336
$a
text
$b
txt
$2
rdacontent
337
$a
computer
$b
c
$2
rdamedia
338
$a
online resource
$b
cr
$2
rdacarrier
500
$a
Source: Dissertations Abstracts International, Volume: 79-10, Section: B.
500
$a
Publisher info.: Dissertation/Thesis.
500
$a
Advisor: Torchilin, Vladimir P.
502
$a
Thesis (Ph.D.)--Northeastern University, 2017.
504
$a
Includes bibliographical references
520
$a
Cancer therapy has undergone remarkable changes in recent times making great progress. However, there still remains an unmet need to completely cure cancer. A major limitation of cancer therapy is the undesired effects on non-target tissues. Using targeted nanocarriers like liposomes can help to enhance delivery of therapeutics to a pathological area, influence the pharmacokinetic profile of the drug and enhance its accumulation in the targeted sites. Modification of the liposome surface is critical for control of liposomal properties and therefore, their biological behavior. Polyethylene glycol (PEG)-modified liposomes have enhanced longevity in blood by escaping clearance by the reticulo-endothelial system (RES), resulting in increased accumulation at the tumor sites via passive targeting owing to the enhanced permeability and retention (EPR) effect. In this study, we took advantage of passive, active and intra-cellular targeting capabilities of liposomes for cancer therapy by modifying their surface with ligands. PEG coated DOX-loaded liposomes were surface-modified with an intracellular delivery agent, octa-arginine (R8) peptide, to facilitate improved cytosolic delivery of DOX. R8 was attached to the distal end of the PEG chain, in a polyethylene glycol-phosphatidylethanolamine (PEG-PE)-based amphiphilic polymer for conjugation with the liposome bilayer and improved access to its site of cellular interaction. Once the R8-coated DOX-loaded liposomes entered the tumor tissue by passive targeting, the exposed R8 was expected to bring about intracellular penetration of the liposomes and cytosolic delivery of DOX. Cellular uptake of these liposomes studied by confocal microscopy and flow cytometry in cancer cells in vitro, highlighted advantages of R8 as a tool for intracellular delivery of the payload, compared to the unmodified liposomes. R8-modified liposomes illustrated superior effects in terms of in vitro cytotoxicity and apoptosis and good tumor growth inhibition in vivo. However, the interaction of R8-liposomes with cancer cells is non-specific. To make the formulation cancer cell-targeted, a second ligand was added to the liposome surface. Dual functional liposomes (DualL) were prepared by modification of liposome-surface with transferrin molecules, in combination with the R8-modification, to target the transferrin receptors (TfRs) that are known to be over-expressed on the surface of many cancer cells. Fluorescently labelled DualL, without the DOX payload, were tested for their interactions with TfR over-expressing A2780 ovarian cancer cells. Flow cytometry and confocal microscopy, clearly indicated better association and internalization of DualL versus R8L, pointing to the involvement of both ligands in these effects. When loaded with DOX, Dual DOX-L showed augmented selective cytotoxicity towards cancer cells versus non-cancer cells in vitro. Cytotoxicity of R8 DOX-L was equivalent in the tested cancer and non-cancer cell lines presenting proof of their non-specificity towards cancer cells. The therapeutic potential of Dual DOX-L was tested in vivo in an A2780 ovarian xenograft model in nude mice. In tumor-bearing mice, higher distribution and accumulation of DOX in tumors was obtained upon i.v. administration of Dual DOX-L compared to other treatment groups. A tumor growth inhibition study demonstrated a clear pattern of suppression in tumor growth for Dual DOX-L treated tumors along the course of treatment. On the whole, these results favor the idea of modification of liposome-surfaces with combinations of ligands that have properties of both cancer-cell targeting and improved intracellular delivery to enhance efficacy of their payloads for cancer therapy.
533
$a
Electronic reproduction.
$b
Ann Arbor, Mich. :
$c
ProQuest,
$d
2023
538
$a
Mode of access: World Wide Web
650
4
$a
Pharmaceutical sciences.
$3
3173021
650
4
$a
Oncology.
$3
751006
653
$a
Cancer
653
$a
Doxorubicin
653
$a
Liposomes
653
$a
Octa-arginine
653
$a
Targeting
653
$a
Transferrin
655
7
$a
Electronic books.
$2
lcsh
$3
542853
690
$a
0572
690
$a
0992
710
2
$a
ProQuest Information and Learning Co.
$3
783688
710
2
$a
Northeastern University.
$b
Pharmaceutics and Drug Delivery Systems Specialization.
$3
3698983
773
0
$t
Dissertations Abstracts International
$g
79-10B.
856
4 0
$u
http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10259198
$z
click for full text (PQDT)
筆 0 讀者評論
館藏地:
全部
電子資源
出版年:
卷號:
館藏
1 筆 • 頁數 1 •
1
條碼號
典藏地名稱
館藏流通類別
資料類型
索書號
使用類型
借閱狀態
預約狀態
備註欄
附件
W9480809
電子資源
11.線上閱覽_V
電子書
EB
一般使用(Normal)
在架
0
1 筆 • 頁數 1 •
1
多媒體
評論
新增評論
分享你的心得
Export
取書館
處理中
...
變更密碼
登入